http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/list Mynewsdesk news feed straight from the source http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/list http://www.mynewsdesk.com/images/redesign/graphics/logos/logo-small.png 128 23 en 15 Thu, 24 Jan 2013 16:12:00 +0000 Gambro announced today that the U.S. Food and Drug Administration (FDA) has expanded the cleared indications for its Molecular Adsorbent Recirculating System® (MARS) to include the treatment of hepatic encephalopathy (HE) due to a decompensation of a chronic liver disease. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-mars-r-receives-fda-510-k-clearance-for-treatment-of-hepatic-encephalopathy-831033?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-mars-r-receives-fda-510-k-clearance-for-treatment-of-hepatic-encephalopathy-831033?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Tue, 04 Dec 2012 12:07:39 +0000 Baxter International Inc. (NYSE:BAX) has entered into a definitive agreement to acquire Gambro AB, a privately held dialysis product company based in Lund, Sweden, for total consideration of 26.5 billion SEK (approximately $4.0 billion USD at current exchange rates). http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/baxter-enhances-renal-therapies-portfolio-with-acquisition-of-gambro-818981?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/baxter-enhances-renal-therapies-portfolio-with-acquisition-of-gambro-818981?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Mon, 15 Oct 2012 15:00:00 +0100 Partnership to integrate Novalung’s membrane gas exchange technology into the Prismaflex platform adding CO2 removal to its therapeutic offering. Simple and reliable CO2 removal integrated in a well established blood purification platform is an unmet medical need in the ICU. It facilitates lung-protective ventilation allowing patients lungs to heal faster and reduce the length of stay in the ICU. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-and-novalung-join-forces-to-address-unmet-medical-need-of-co2-removal-in-the-intensive-care-unit-803375?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-and-novalung-join-forces-to-address-unmet-medical-need-of-co2-removal-in-the-intensive-care-unit-803375?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Thu, 24 May 2012 09:23:00 +0100 ERA-EDTA is one of the most important congresses within clinical nephrology, dialysis, renal transplantation and related subjects. During May 24–27 visitors will be able to see the latest innovations from Gambro. Highlights: Individualized Quality-assured Dialysis, SelectBag® Citrate, Diascan, HemoControl™, Gambro Water Systems, Lunch symposium with Dr.Ingrid Ledebo http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-at-the-49th-era-edta-congress-may-24-27-2012-in-paris-france-765168?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-at-the-49th-era-edta-congress-may-24-27-2012-in-paris-france-765168?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Mon, 16 Apr 2012 09:00:00 +0100 Gambro introduces SelectBag® Citrate to improve quality of life for hemodialysis patients. Improving quality of life for hemodialysis patients is a primary goal of the innovative new SelectBag® Citrate concentrate from Gambro — the unique citrate-containing, acetate-free dialysis fluid for regular hemodialysis and hemodiafiltration treatment. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-introduces-selectbag-r-citrate-to-improve-quality-of-life-for-hemodialysis-patients-750749?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-introduces-selectbag-r-citrate-to-improve-quality-of-life-for-hemodialysis-patients-750749?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Mon, 06 Feb 2012 09:01:00 +0000 A research consortium headed by Gambro in Germany, consisting of researchers from different disciplines, has received a project grant of 2.1 million euros from the German Federal Ministry of Education and Research. The project aims to investigate a new generation of dialysis membranes to improve the treatment of chronic inflammation in End Stage Renal Disease patients. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/bmbf-funds-a-research-project-coordinated-by-gambro-to-investigate-chronic-inflammation-in-esrd-patients-729924?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/bmbf-funds-a-research-project-coordinated-by-gambro-to-investigate-chronic-inflammation-in-esrd-patients-729924?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Thu, 06 Oct 2011 13:12:00 +0100 Effective CRRT is largely determined by adequate anticoagulation of the extracorporeal circuit. With FleXitrate, Gambro makes performing regional citrate anticoagulation simple and safe. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-introduces-flexitrate-the-complete-citrate-calcium-offering-for-continuous-renal-replacement-therapy-crrt-690807?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-introduces-flexitrate-the-complete-citrate-calcium-offering-for-continuous-renal-replacement-therapy-crrt-690807?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Fri, 15 Jul 2011 10:00:00 +0100 It all started in 1984, with the production of single lumen catheters. Today, more than 70 employees work at Gambro Kathetertechnik in Hechingen, which recently celebrated 25 years of catheter production. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-celebrates-25-years-of-catheter-development-in-its-manufacturing-plant-in-hechingen-germany-661799?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-celebrates-25-years-of-catheter-development-in-its-manufacturing-plant-in-hechingen-germany-661799?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Tue, 05 Jul 2011 10:00:00 +0100 On June 24, 2011, Gambro hosted a Lunch Symposium at the ERA-EDTA Congress in Prague which attracted great interest from the Congress delegates. The main topic discussed was different therapy options for individualized quality-assured dialysis. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-industry-symposium-therapy-options-for-individualized-quality-assured-dialysis-at-the-era-edta-congress-in-prague-658745?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-industry-symposium-therapy-options-for-individualized-quality-assured-dialysis-at-the-era-edta-congress-in-prague-658745?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Wed, 08 Jun 2011 16:47:00 +0100 On June 1st, Gambro signed an agreement with Italian Trade Union representatives at the Italian Ministry of Economic Development (Ministero dello Sviluppo Economico) to continue with the optimization of the bloodline manufacturing foot print as announced on January 27, 2011. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-signs-agreement-with-italian-trade-unions-to-optimize-the-bloodline-manufacturing-in-medolla-italy-654304?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-signs-agreement-with-italian-trade-unions-to-optimize-the-bloodline-manufacturing-in-medolla-italy-654304?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Mon, 23 May 2011 16:48:00 +0100 As part of the ongoing work to make Gambro more efficient and cost effective, a decision has been made to move the Gambro headquarters from Stockholm to Lund, Sweden. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-headquarters-moves-from-stockholm-to-lund-sweden-654306?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-headquarters-moves-from-stockholm-to-lund-sweden-654306?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Wed, 06 Apr 2011 16:37:00 +0100 Gambro is donating 10M Japanese Yen, equivalent of app. 720 000 SEK, to the Japanese Red Cross as part of its continued support to the people of Japan during this time of crisis. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-makes-monetary-donation-to-the-red-cross-in-japan-654299?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-makes-monetary-donation-to-the-red-cross-in-japan-654299?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Thu, 27 Jan 2011 12:51:00 +0000 Gambro today announces its decision to cease bloodline manufacturing in Medolla, Italy, in order to optimize its global bloodline manufacturing footprint. The company has decided to outsource a number of the bloodline manufacturing activities currently performed at the site, and to consolidate the remaining bloodline activities into its manufacturing sites in Přerov, Shanghai and Tijuana. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-optimizes-its-global-bloodline-manufacturing-footprint-611003?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-optimizes-its-global-bloodline-manufacturing-footprint-611003?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Mon, 27 Dec 2010 12:57:00 +0000 Gambro today announced it has finalized* the sale of its global peritoneal dialysis (PD) business to Fresenius Medical Care. The ownership of Gambro’s solutions manufacturing plant in Canosa, Italy will coincide with the transfer of the manufacturing license expected to occur in early 2011. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-finalizes-the-sale-of-its-global-pd-business-to-fresenius-medical-care-611009?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-finalizes-the-sale-of-its-global-pd-business-to-fresenius-medical-care-611009?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Wed, 13 Oct 2010 14:02:00 +0100 Gambro today announced that it will significantly expand its capacity for producing dialyzers with synthetic membranes at its existing dialyzer plant in Hechingen, Germany. With the planned investment in production capacity, Gambro will be adding more than 8 million additional dialyzers annually to meet growing market demands. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-invests-in-additional-dialyzer-production-capacity-at-hechingen-germany-611085?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-invests-in-additional-dialyzer-production-capacity-at-hechingen-germany-611085?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Thu, 23 Sep 2010 16:29:00 +0100 The Prismaflex eXeed II software is the latest improvement to the Prismaflex® system, the most widely used continuous renal replacement therapy device for the treatment of critically ill patients with acute kidney injury. The software has two important components, one pertaining to the provision of citrate anticoagulation and the other allowing for use of the Gambro MARS liver support therapy. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-introduces-the-prismaflex-exeed-ii-system-for-citrate-anticoagulation-with-integrated-calcium-management-and-mars-r-system-compatibility-654297?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-introduces-the-prismaflex-exeed-ii-system-for-citrate-anticoagulation-with-integrated-calcium-management-and-mars-r-system-compatibility-654297?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Thu, 26 Aug 2010 16:25:00 +0100 Gambro and Fresenius today announced that they have signed a framework agreement for the sale of Gambro’s global peritoneal dialysis (PD) business and related assets. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-makes-the-strategic-decision-to-focus-on-its-core-businesses-and-sell-its-global-pd-business-to-fresenius-medical-care-654296?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-makes-the-strategic-decision-to-focus-on-its-core-businesses-and-sell-its-global-pd-business-to-fresenius-medical-care-654296?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Mon, 05 Jul 2010 16:20:00 +0100 Gambro hosted a symposium at the ERA-EDTA Congress in Munich presenting the 2009 survey results “Dialysis Opinions – Facilitating dialysis delivery”. The majority of the nephrology professionals that responded would like to see extended use of biofeedback, such as automatic control of dialysis dose and blood volume, to facilitate dialysis delivery and improve the patient outcome. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/facilitating-dialysis-delivery-generated-high-interest-among-nephrology-professionals-at-era-edta-654295?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/facilitating-dialysis-delivery-generated-high-interest-among-nephrology-professionals-at-era-edta-654295?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Fri, 25 Jun 2010 16:15:00 +0100 Gambro today launches a brand new innovation in long-term hemodialysis catheters at the 47th congress of the ERA-EDTA (European Renal Association – European Dialysis and Transplant Association), in Munich. The EverFlow Dolphin Protect’s unique coating technology makes it the first on the market to provide antimicrobial protection without the release of active agents1. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-introduces-everflow-dolphin-protect-the-first-hemodialysis-catheter-of-its-kind-654293?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/gambro-introduces-everflow-dolphin-protect-the-first-hemodialysis-catheter-of-its-kind-654293?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB Wed, 21 Apr 2010 16:05:00 +0100 A study presented at the 45th Annual Meeting of the European Association for the Study of Liver (EASL) adds to the growing body of evidence supporting the clinical benefits of Gambro’s Molecular Adsorbents Recirculating System® (MARS) therapy. http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/mars-r-therapy-shows-promise-in-largest-clinical-trial-for-patients-with-acute-on-chronic-liver-failure-654292?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/uk/pressroom/gambro/pressrelease/view/mars-r-therapy-shows-promise-in-largest-clinical-trial-for-patients-with-acute-on-chronic-liver-failure-654292?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gambro AB